Enterosept tablets p/o 100mg №10×2

Name:
Enterosept No. 30
Description:
Coated tablets, round, biconvex, yellow. The main active ingredient Nifuroxazide Release form Tablets Dosage 100 mg Indications for use – treatment of acute diarrhea of bacterial origin caused by susceptible strains of Staphylococcus spp., Salmonella spp., Escherichia coli in the absence of signs of invasion (for example, deterioration in general condition, fever, toxic infection, etc.). The dose and method of rehydration (oral or intravenous) are determined depending on the severity of diarrhea, age, condition of the patient, the presence of concomitant diseases. Dosage and administration Enterosept tablets are intended for oral administration. Adults and children over 7 years of age are prescribed 2 tablets 4 times a day. The drug is taken regardless of food intake at regular intervals (every 6 hours). The tablet should be swallowed whole with a small amount of water, without chewing or crushing. Enterosept tablets for the treatment of acute diarrhea are recommended to be taken within 3 days. If after this the symptoms do not disappear, you should consult a doctor. During the treatment of acute diarrhea, constant oral replenishment of fluid deficiency in the body is mandatory, depending on the general condition of the patient. Use during pregnancy and lactation Pregnancy period. There are no clinical data regarding the use of nifuroxazide during pregnancy. Animal studies do not show any direct or indirect effects on the course of pregnancy, the development of the embryo or fetus, or the course of childbirth. The physician should carefully evaluate the benefit / risk ratio when prescribing nifuroxazide to pregnant women. breastfeeding period. Nifuroxazide is not absorbed from the gastrointestinal tract. However, due to the lack of sufficient clinical data, caution should be exercised when prescribing nifuroxazide during lactation. The ability to influence the reaction rate when driving vehicles or working with other mechanisms Pregnancy period. There are no clinical data regarding the use of nifuroxazide during pregnancy. Animal studies do not show any direct or indirect effects on the course of pregnancy, the development of the embryo or fetus, or the course of childbirth. The physician should carefully evaluate the benefit / risk ratio when prescribing nifuroxazide to pregnant women. breastfeeding period. Nifuroxazide is not absorbed from the gastrointestinal tract. However, due to the lack of sufficient clinical data, caution should be exercised when prescribing nifuroxazide during lactation. Precautions In case of persistent diarrhea after 3 days of treatment, an in-depth diagnosis should be made to determine the cause of the symptoms and consideration should be given to starting antibiotic therapy. In the case of severe invasive diarrhea, antibiotic therapy is necessary, since nifuroxazide is not absorbed from the gastrointestinal tract. During treatment with nifuroxazide, the use of alcoholic beverages is contraindicated, since the drug increases the body’s sensitivity to alcohol and can provoke a disulfiram-like reaction. If symptoms of dehydration appear during the period of treatment with the drug, it is necessary, depending on the clinical condition of the patient, to carry out oral rehydration therapy (for adults – about 2 liters of fluid per day). Nifuroxazide should be used with a strict diet, excluding juices, raw vegetables and fruits, spicy and indigestible foods. Interaction with other drugs Alcohol consumption during treatment with nifuroxazide may cause disulfiram-like reactions. While taking nifuroxazide, the simultaneous administration of other oral agents should be avoided due to the strong adsorption properties of the drug. Contraindications Enterosept is contraindicated for use in case of hypersensitivity to any of the components of the drug, as well as in case of allergic reactions to 5-nitrofuran derivatives. Children’s age up to 7 years due to the peculiarities of the dosage form. One tablet contains: active substance: nifuroxazide 100 mg; excipients: povidone, sodium starch glycolate (type A), calcium stearate, microcrystalline cellulose; shell: polyvinyl alcohol, polysorbate 80, talc, macrogoal text Overdose Not described. In case of overdose, gastric lavage and symptomatic treatment are recommended. Side effects From the gastrointestinal tract: In case of individual hypersensitivity to nifuroxazide, abdominal pain, nausea and exacerbation of diarrhea may occur. In the event of such symptoms of slight intensity, there is no need to apply special therapy or stop taking Enterosept. With the development of the above symptoms of significant intensity, the drug should be discontinued. In the future, the patient should not use nitrofuran derivatives. On the part of the skin and subcutaneous tissue: Rarely – skin reactions in the form of a rash. From the side of the hematopoietic and lymphatic system: A case of granulocytopenia is described. Usually nifuroxazide is well tolerated, side effects are extremely rare. Storage conditions At a temperature not exceeding 25 ° C, in a place protected from light and moisture. Keep out of the reach of children. Buy Enterosept tablets p/o 100mg №10×2 Price for Enterosept tablets p/o 100mg №10×2